Clinical Trial: Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Study to Assess the Effectiveness of Teriparatide (FORTEO) for Increasing Bone Mass and Improving Bone Strength in Adults Affected With Osteogenesis Imperfecta (OI)
Brief Summary: The purpose of this study is to determine the effectiveness of teriparatide (FORTEO), which is human parathyroid hormone 1-34, for increasing bone mass and improving bone structure in adults affected with Osteogenesis Imperfecta (OI).
Detailed Summary:
The purpose of this study is to determine the effectiveness of teriparatide (FORTEO), which is human parathyroid hormone 1-34, for increasing bone mass and improving bone structure in adults affected with Osteogenesis Imperfecta (OI). Osteogenesis imperfecta is an inherited disorder of type I collagen, a major component of bones, and is characterized by multiple fractures and deformities. OI affects approximately 1-2 of every 10,000 individuals. Virtually all of the studies of potential treatments for OI have evaluated the effects of medications only on children with OI. There is no cure for osteogenesis imperfecta and there is no established medical therapy for adults with the disorder. There are very limited data concerning the usefulness of parathyroid hormone therapy in OI. An effective anabolic therapy for the treatment of adult patients with OI could be a valuable asset to the affected patients. In this study, the working hypothesis is that individuals affected with OI who are treated with Forteo will experience increased spine and hip bone mineral density and an increase in bone strength. Although Forteo is not expected to change the defect in the collagen produced, but is postulated to increase the quantity of bone formed and improve bone strength.
This will be a placebo controlled, double blinded trial; half the patients will receive Forteo 20 ug/day SQ. Adult patients (age at least 18 yrs) with OI will be enrolled for a treatment duration of 18 months. Blood, urine, and bone density/strength tests will be done during the study to assess efficacy and safety.
Sponsor: Oregon Health and Science University
Current Primary Outcome: The primary aim of this study is to assess whether there will be a significant increase in spine bone mineral density (BMD) as a result from Forteo therapy. [ Time Frame: 01/01/11 ]
Original Primary Outcome: The primary aim of this study is to assess whether an increase in BMD will result from the use of rhPTH.
Current Secondary Outcome: Secondary aims are to determine if Forteo therapy will increase hip and radial BMD, increase estimated vertebral strength, and decrease the rate of fragility fractures in individuals affected with OI. [ Time Frame: 01/01/11 ]
Original Secondary Outcome: A secondary aim is to determine if PTH therapy will decrease fragility fractures in individuals affected with OI.
Information By: Oregon Health and Science University
Dates:
Date Received: August 16, 2005
Date Started: June 2005
Date Completion:
Last Updated: October 30, 2013
Last Verified: October 2013
